Skip to main content
SpringerLink
Log in

Targeting β-Arrestins in the Treatment of Psychiatric and Neurological Disorders

CNS Drugs volume 35, pages 253–264 (2021)Cite this article

Abstract

Therapies for psychiatric and neurological disorders have been in the development and refinement process for the past 5 decades. Yet, most of these therapies lack optimal therapeutic efficacy and have multiple debilitating side effects. Recent advances in understanding the pathophysiological processes of psychiatric and neurological disorders have revealed an important role for β-arrestins, which are important regulators of G-protein-coupled receptor (GPCR) function, including desensitization and intracellular signaling. These findings have pushed β-arrestins to the forefront as potential therapeutic targets. Here, we highlight current knowledge on β-arrestin functions in certain psychiatric and neurological disorders (schizophrenia, Parkinson’s disease, and substance abuse disorders), and how this has been leveraged to develop new therapeutic strategies. Furthermore, we discuss the obstacles impacting the field of β-arrestin-based therapeutic development and future approaches that might help advance strategies to develop optimal β-arrestin-based therapies.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

USD 39.95

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Fig. 1

References

  1. Lagerstrom MC, Schioth HB. Structural diversity of G protein-coupled receptors and significance for drug discovery. Nat Rev. 2008;7(4):339–57.

    Google Scholar 

  2. Rask-Andersen M, Masuram S, Schioth HB. The druggable genome: evaluation of drug targets in clinical trials suggests major shifts in molecular class and indication. Annu Rev Pharmacol Toxicol. 2014;54:9–26.

    Article  CAS  PubMed  Google Scholar 

  3. Overington JP, Al-Lazikani B, Hopkins AL. How many drug targets are there? Nat Rev. 2006;5(12):993–6.

    CAS  Google Scholar 

  4. Lefkowitz RJ, Shenoy SK. Transduction of receptor signals by beta-arrestins. Sci (New York, NY). 2005;308(5721):512–7.

    Article  CAS  Google Scholar 

  5. Pfister C, Chabre M, Plouet J, Tuyen VV, De Kozak Y, Faure JP, et al. Retinal S antigen identified as the 48K protein regulating light-dependent phosphodiesterase in rods. Sci (New York, NY). 1985;228(4701):891–3.

    Article  CAS  Google Scholar 

  6. Attramadal H, Arriza JL, Aoki C, Dawson TM, Codina J, Kwatra MM, et al. Beta-arrestin2, a novel member of the arrestin/beta-arrestin gene family. J Biol Chem. 1992;267(25):17882–90.

    Article  CAS  PubMed  Google Scholar 

  7. Lohse MJ, Benovic JL, Codina J, Caron MG, Lefkowitz RJ. beta-Arrestin: a protein that regulates beta-adrenergic receptor function. Sci (New York, NY). 1990;248(4962):1547–50.

    Article  CAS  Google Scholar 

  8. Ferguson SS, Downey WE, Colapietro AM, Barak LS, Menard L, Caron MG. Role of beta-arrestin in mediating agonist-promoted G protein-coupled receptor internalization. Sci (New York, NY). 1996;271(5247):363–6.

    Article  CAS  Google Scholar 

  9. Laporte SA, Oakley RH, Zhang J, Holt JA, Ferguson SS, Caron MG, et al. The beta2-adrenergic receptor/betaarrestin complex recruits the clathrin adaptor AP-2 during endocytosis. Proc Natl Acad Sci USA. 1999;96(7):3712–7.

    Article  CAS  PubMed  Google Scholar 

  10. Krupnick JG, Goodman OB Jr, Keen JH, Benovic JL. Arrestin/clathrin interaction. Localization of the clathrin binding domain of nonvisual arrestins to the carboxy terminus. J Biol Chem. 1997;272(23):15011–6.

    Article  CAS  PubMed  Google Scholar 

  11. Barak LS, Ferguson SS, Zhang J, Caron MG. A beta-arrestin/green fluorescent protein biosensor for detecting G protein-coupled receptor activation. J Biol Chem. 1997;272(44):27497–500.

    Article  CAS  PubMed  Google Scholar 

  12. Bohn LM, Gainetdinov RR, Lin FT, Lefkowitz RJ, Caron MG. Mu-opioid receptor desensitization by beta-arrestin-2 determines morphine tolerance but not dependence. Nature. 2000;408(6813):720–3.

    Article  CAS  PubMed  Google Scholar 

  13. Bohn LM, Gainetdinov RR, Sotnikova TD, Medvedev IO, Lefkowitz RJ, Dykstra LA, et al. Enhanced rewarding properties of morphine, but not cocaine, in beta(arrestin)-2 knock-out mice. J Neurosci. 2003;23(32):10265–73.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Bohn LM, Lefkowitz RJ, Gainetdinov RR, Peppel K, Caron MG, Lin FT. Enhanced morphine analgesia in mice lacking beta-arrestin 2. Sci (New York, NY). 1999;286(5449):2495–8.

    Article  CAS  Google Scholar 

  15. Luttrell LM, Ferguson SS, Daaka Y, Miller WE, Maudsley S, Della Rocca GJ, et al. Beta-arrestin-dependent formation of beta2 adrenergic receptor-Src protein kinase complexes. Sci (New York, NY). 1999;283(5402):655–61.

    Article  CAS  Google Scholar 

  16. Pierce KL, Maudsley S, Daaka Y, Luttrell LM, Lefkowitz RJ. Role of endocytosis in the activation of the extracellular signal-regulated kinase cascade by sequestering and nonsequestering G protein-coupled receptors. Proc Natl Acad Sci USA. 2000;97(4):1489–94.

    Article  CAS  PubMed  Google Scholar 

  17. Shenoy SK, Drake MT, Nelson CD, Houtz DA, Xiao K, Madabushi S, et al. beta-arrestin-dependent, G protein-independent ERK1/2 activation by the beta2 adrenergic receptor. J Biol Chem. 2006;281(2):1261–73.

    Article  CAS  PubMed  Google Scholar 

  18. Urban JD, Clarke WP, von Zastrow M, Nichols DE, Kobilka B, Weinstein H, et al. Functional selectivity and classical concepts of quantitative pharmacology. J Pharmacol Exp Ther. 2007;320(1):1–13.

    Article  CAS  PubMed  Google Scholar 

  19. Mailman RB. GPCR functional selectivity has therapeutic impact. Trends Pharmacol Sci. 2007;28(8):390–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Disease GBD, Injury I, Prevalence C. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392(10159):1789–858.

    Article  Google Scholar 

  21. Carbon M, Correll CU. Thinking and acting beyond the positive: the role of the cognitive and negative symptoms in schizophrenia. CNS Spectr. 2014;19(1):38–52.

    PubMed  Google Scholar 

  22. Seeman P, Kapur S. Schizophrenia: more dopamine, more D2 receptors. Proc Natl Acad Sci USA. 2000;97(14):7673–5.

    Article  CAS  PubMed  Google Scholar 

  23. McCutcheon R, Beck K, Jauhar S, Howes OD. Defining the locus of dopaminergic dysfunction in schizophrenia: a meta-analysis and test of the mesolimbic hypothesis. Schizophr Bull. 2018;44(6):1301–11.

    Article  PubMed  Google Scholar 

  24. Leyton M, Boileau I, Benkelfat C, Diksic M, Baker G, Dagher A. Amphetamine-induced increases in extracellular dopamine, drug wanting, and novelty seeking: a PET/[11C]raclopride study in healthy men. Neuropsychopharmacology. 2002;27(6):1027–35.

    Article  CAS  PubMed  Google Scholar 

  25. Janowsky DS, Risch C. Amphetamine psychosis and psychotic symptoms. Psychopharmacology. 1979;65(1):73–7.

    Article  CAS  PubMed  Google Scholar 

  26. Angrist B, Rotrosen J, Gershon S. Responses to apomorphine, amphetamine, and neuroleptics in schizophrenic subjects. Psychopharmacology. 1980;67(1):31–8.

    Article  CAS  PubMed  Google Scholar 

  27. Slifstein M, van de Giessen E, Van Snellenberg J, Thompson JL, Narendran R, Gil R, et al. Deficits in prefrontal cortical and extrastriatal dopamine release in schizophrenia: a positron emission tomographic functional magnetic resonance imaging study. JAMA Psychiatry. 2015;72(4):316–24.

    Article  PubMed  PubMed Central  Google Scholar 

  28. Kebabian JW, Calne DB. Multiple receptors for dopamine. Nature. 1979;277(5692):93–6.

    Article  CAS  PubMed  Google Scholar 

  29. Nishi A, Snyder GL, Greengard P. Bidirectional regulation of DARPP-32 phosphorylation by dopamine. J Neurosci. 1997;17(21):8147–55.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Gainetdinov RR, Premont RT, Bohn LM, Lefkowitz RJ, Caron MG. Desensitization of G protein-coupled receptors and neuronal functions. Annu Rev Neurosci. 2004;27:107–44.

    Article  CAS  PubMed  Google Scholar 

  31. Beaulieu JM, Gainetdinov RR. The physiology, signaling, and pharmacology of dopamine receptors. Pharmacol Rev. 2011;63(1):182–217.

    Article  CAS  PubMed  Google Scholar 

  32. Zurkovsky L, Sedaghat K, Ahmed MR, Gurevich VV, Gurevich EV. Arrestin-2 and arrestin-3 differentially modulate locomotor responses and sensitization to amphetamine. Neuropharmacology. 2017;15(121):20–9.

    Article  Google Scholar 

  33. Beaulieu JM, Sotnikova TD, Marion S, Lefkowitz RJ, Gainetdinov RR, Caron MG. An Akt/beta-arrestin 2/PP2A signaling complex mediates dopaminergic neurotransmission and behavior. Cell. 2005;122(2):261–73.

    Article  CAS  PubMed  Google Scholar 

  34. McDonald PH, Chow CW, Miller WE, Laporte SA, Field ME, Lin FT, et al. Beta-arrestin 2: a receptor-regulated MAPK scaffold for the activation of JNK3. Sci (New York, NY). 2000;290(5496):1574–7.

    Article  CAS  Google Scholar 

  35. Urs NM, Daigle TL, Caron MG. A dopamine D1 receptor-dependent beta-arrestin signaling complex potentially regulates morphine-induced psychomotor activation but not reward in mice. Neuropsychopharmacology. 2011;36(3):551–8.

    Article  CAS  PubMed  Google Scholar 

  36. Urs NM, Snyder JC, Jacobsen JP, Peterson SM, Caron MG. Deletion of GSK3beta in D2R-expressing neurons reveals distinct roles for beta-arrestin signaling in antipsychotic and lithium action. Proc Natl Acad Sci USA. 2012;109(50):20732–7.

    Article  CAS  PubMed  Google Scholar 

  37. Urs NM, Gee SM, Pack TF, McCorvy JD, Evron T, Snyder JC, et al. Distinct cortical and striatal actions of a beta-arrestin-biased dopamine D2 receptor ligand reveal unique antipsychotic-like properties. Proc Natl Acad Sci USA. 2016;113(50):E8178–86.

    Article  CAS  PubMed  Google Scholar 

  38. Li YC, Panikker P, Xing B, Yang SS, Alexandropoulos C, McEachern EP, et al. Deletion of glycogen synthase kinase-3beta in D2 receptor-positive neurons ameliorates cognitive impairment via nmda receptor-dependent synaptic plasticity. Biol Psychiatry. 2020;87(8):745–55.

    Article  CAS  PubMed  Google Scholar 

  39. Li YC, Xi D, Roman J, Huang YQ, Gao WJ. Activation of glycogen synthase kinase-3 beta is required for hyperdopamine and D2 receptor-mediated inhibition of synaptic NMDA receptor function in the rat prefrontal cortex. J Neurosci. 2009;29(49):15551–63.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Creese I, Burt DR, Snyder SH. Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Sci (New York, NY). 1976;192(4238):481–3.

    Article  CAS  Google Scholar 

  41. Haro JM, Suarez D, Novick D, Brown J, Usall J, Naber D, et al. Three-year antipsychotic effectiveness in the outpatient care of schizophrenia: observational versus randomized studies results. Eur Neuropsychopharmacol. 2007;17(4):235–44.

    Article  CAS  PubMed  Google Scholar 

  42. Jeste DV, Lacro JP, Palmer B, Rockwell E, Harris MJ, Caligiuri MP. Incidence of tardive dyskinesia in early stages of low-dose treatment with typical neuroleptics in older patients. Am J Psychiatry. 1999;156(2):309–11.

    Article  CAS  PubMed  Google Scholar 

  43. Kroeze WK, Hufeisen SJ, Popadak BA, Renock SM, Steinberg S, Ernsberger P, et al. H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology. 2003;28(3):519–26.

    Article  CAS  PubMed  Google Scholar 

  44. Chowdhury NI, Remington G, Kennedy JL. Genetics of antipsychotic-induced side effects and agranulocytosis. Curr Psychiatry Rep. 2011;13(2):156–65.

    Article  PubMed  Google Scholar 

  45. Leung JY, Barr AM, Procyshyn RM, Honer WG, Pang CC. Cardiovascular side-effects of antipsychotic drugs: the role of the autonomic nervous system. Pharmacol Ther. 2012;135(2):113–22.

    Article  CAS  PubMed  Google Scholar 

  46. Lieberman JA. Dopamine partial agonists: a new class of antipsychotic. CNS Drugs. 2004;18(4):251–67.

    Article  CAS  PubMed  Google Scholar 

  47. Mailman RB, Murthy V. Third generation antipsychotic drugs: partial agonism or receptor functional selectivity? Curr Pharm Des. 2010;16(5):488–501.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Masri B, Salahpour A, Didriksen M, Ghisi V, Beaulieu JM, Gainetdinov RR, et al. Antagonism of dopamine D2 receptor/beta-arrestin 2 interaction is a common property of clinically effective antipsychotics. Proc Natl Acad Sci USA. 2008;105(36):13656–61.

    Article  CAS  PubMed  Google Scholar 

  49. Klewe IV, Nielsen SM, Tarpo L, Urizar E, Dipace C, Javitch JA, et al. Recruitment of beta-arrestin2 to the dopamine D2 receptor: insights into anti-psychotic and anti-parkinsonian drug receptor signaling. Neuropharmacology. 2008;54(8):1215–22.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. Deslauriers J, Desmarais C, Sarret P, Grignon S. alpha-Lipoic acid interaction with dopamine D2 receptor-dependent activation of the Akt/GSK-3beta signaling pathway induced by antipsychotics: potential relevance for the treatment of schizophrenia. J Mol Neurosci. 2013;50(1):134–45.

    Article  CAS  PubMed  Google Scholar 

  51. Slifstein M, van de Giessen E, Van Snellenberg J, Thompson JL, Narendran R, Gil R, et al. Deficits in prefrontal cortical and extrastriatal dopamine release in schizophrenia: a positron emission tomographic functional magnetic resonance imaging study. JAMA Psychiatry. 2015.

  52. Allen JA, Yost JM, Setola V, Chen X, Sassano MF, Chen M, et al. Discovery of beta-arrestin-biased dopamine D2 ligands for probing signal transduction pathways essential for antipsychotic efficacy. Proc Natl Acad Sci USA. 2011;108(45):18488–93.

    Article  CAS  PubMed  Google Scholar 

  53. Park SM, Chen M, Schmerberg CM, Dulman RS, Rodriguiz RM, Caron MG, et al. Effects of beta-arrestin-biased dopamine D2 receptor ligands on schizophrenia-like behavior in hypoglutamatergic mice. Neuropsychopharmacology. 2016;41(3):704–15.

    Article  CAS  PubMed  Google Scholar 

  54. Urs NM, Peterson SM, Caron MG. New concepts in dopamine D2 receptor biased signaling and implications for schizophrenia therapy. Biol Psychiatry. 2017;81(1):78–85.

    Article  CAS  PubMed  Google Scholar 

  55. Agren R, Arhem P, Nilsson J, Sahlholm K. the beta-arrestin-biased dopamine D2 receptor ligand, UNC9994, is a partial agonist at g-protein-mediated potassium channel activation. Int J Neuropsychopharmacol. 2018;21(12):1102–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  56. Karschin C, Dissmann E, Stuhmer W, Karschin A. IRK(1–3) and GIRK(1–4) inwardly rectifying K+ channel mRNAs are differentially expressed in the adult rat brain. J Neurosci. 1996;16(11):3559–70.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  57. Marcott PF, Mamaligas AA, Ford CP. Phasic dopamine release drives rapid activation of striatal D2-receptors. Neuron. 2014;84(1):164–76.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  58. Jiang M, Spicher K, Boulay G, Wang Y, Birnbaumer L. Most central nervous system D2 dopamine receptors are coupled to their effectors by Go. Proc Natl Acad Sci USA. 2001;98(6):3577–82.

    Article  CAS  PubMed  Google Scholar 

  59. Corvol JC, Studler JM, Schonn JS, Girault JA, Herve D. Galpha(olf) is necessary for coupling D1 and A2a receptors to adenylyl cyclase in the striatum. J Neurochem. 2001;76(5):1585–8.

    Article  CAS  PubMed  Google Scholar 

  60. Erdtmann-Vourliotis M, Mayer P, Ammon S, Riechert U, Hollt V. Distribution of G-protein-coupled receptor kinase (GRK) isoforms 2, 3, 5 and 6 mRNA in the rat brain. Brain Res Mol Brain Res. 2001;95(1–2):129–37.

    Article  CAS  PubMed  Google Scholar 

  61. Amar S, Shaltiel G, Mann L, Shamir A, Dean B, Scarr E, et al. Possible involvement of post-dopamine D2 receptor signalling components in the pathophysiology of schizophrenia. Int J Neuropsychopharmacol. 2008;11(2):197–205.

    Article  CAS  PubMed  Google Scholar 

  62. Ahmed MR, Gurevich VV, Dalby KN, Benovic JL, Gurevich EV. Haloperidol and clozapine differentially affect the expression of arrestins, receptor kinases, and extracellular signal-regulated kinase activation. J Pharmacol Exp Ther. 2008;325(1):276–83.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  63. Liou YJ, Wang YC, Chen JY, Chen ML, Chen TT, Bai YM, et al. The coding-synonymous polymorphism rs1045280 (Ser280Ser) in beta-arrestin 2 (ARRB2) gene is associated with tardive dyskinesia in Chinese patients with schizophrenia. Eur J Neurol. 2008;15(12):1406–8.

    Article  PubMed  Google Scholar 

  64. Shen Y, McCorvy JD, Martini ML, Rodriguiz RM, Pogorelov VM, Ward KM, et al. D2 dopamine receptor G protein-biased partial agonists based on cariprazine. J Med Chem. 2019;62(9):4755–71.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  65. Arnsten AF, Girgis RR, Gray DL, Mailman RB. Novel dopamine therapeutics for cognitive deficits in schizophrenia. Biol Psychiatry. 2017;81(1):67–77.

    Article  CAS  PubMed  Google Scholar 

  66. Yang Y, Lee SM, Imamura F, Gowda K, Amin S, Mailman RB. D1 dopamine receptors intrinsic activity and functional selectivity affect working memory in prefrontal cortex. Mol Psychiatry. 2018.

  67. de Lau LM, Breteler MM. Epidemiology of Parkinson’s disease. Lancet Neurol. 2006;5(6):525–35.

    Article  PubMed  Google Scholar 

  68. Block ML, Hong JS. Chronic microglial activation and progressive dopaminergic neurotoxicity. Biochem Soc Trans. 2007;35(Pt 5):1127–32.

    Article  CAS  PubMed  Google Scholar 

  69. Tiwari PC, Pal R. The potential role of neuroinflammation and transcription factors in Parkinson disease. Dial Clin Neurosci. 2017;19(1):71–80.

    Article  Google Scholar 

  70. Liddelow SA, Barres BA. Reactive astrocytes: production, function, and therapeutic potential. Immunity. 2017;46(6):957–67.

    Article  CAS  PubMed  Google Scholar 

  71. Wang Q, Liu Y, Zhou J. Neuroinflammation in Parkinson’s disease and its potential as therapeutic target. Transl Neurodegener. 2015;4:19.

    Article  PubMed  PubMed Central  Google Scholar 

  72. Sharma D, Parameswaran N. Multifaceted role of beta-arrestins in inflammation and disease. Genes Immun. 2015;16(8):576.

    Article  CAS  PubMed  Google Scholar 

  73. Witherow DS, Garrison TR, Miller WE, Lefkowitz RJ. beta-Arrestin inhibits NF-kappaB activity by means of its interaction with the NF-kappaB inhibitor IkappaBalpha. Proc Natl Acad Sci USA. 2004;101(23):8603–7.

    Article  CAS  PubMed  Google Scholar 

  74. Sharma M, Flood PM. beta-arrestin2 regulates the anti-inflammatory effects of Salmeterol in lipopolysaccharide-stimulated BV2 cells. J Neuroimmunol. 2018;15(325):10–9.

    Article  Google Scholar 

  75. Feng X, Wu CY, Burton FH, Loh HH, Wei LN. beta-arrestin protects neurons by mediating endogenous opioid arrest of inflammatory microglia. Cell Death Differ. 2014;21(3):397–406.

    Article  CAS  PubMed  Google Scholar 

  76. Du RH, Zhou Y, Xia ML, Lu M, Ding JH, Hu G. alpha-Synuclein disrupts the anti-inflammatory role of Drd2 via interfering beta-arrestin2-TAB1 interaction in astrocytes. J Neuroinflammation. 2018;15(1):258.

    Article  PubMed  PubMed Central  Google Scholar 

  77. Zhu J, Hu Z, Han X, Wang D, Jiang Q, Ding J, et al. Dopamine D2 receptor restricts astrocytic NLRP3 inflammasome activation via enhancing the interaction of beta-arrestin2 and NLRP3. Cell Death Differ. 2018;25(11):2037–49.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  78. Pan J, Li H, Zhang B, Xiong R, Zhang Y, Kang WY, et al. Small peptide inhibitor of JNK3 protects dopaminergic neurons from MPTP induced injury via inhibiting the ASK1-JNK3 signaling pathway. PLoS ONE. 2015;10(4):e0119204.

    Article  PubMed  PubMed Central  Google Scholar 

  79. Ahmed MR, Zhan X, Song X, Kook S, Gurevich VV, Gurevich EV. Ubiquitin ligase parkin promotes Mdm2-arrestin interaction but inhibits arrestin ubiquitination. Biochemistry. 2011;50(18):3749–63.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  80. Tieu K. A guide to neurotoxic animal models of Parkinson’s disease. Cold Spring Harb Perspect Med. 2011;1(1):a009316.

    Article  PubMed  PubMed Central  Google Scholar 

  81. Wu N, Song L, Yang X, Yuan W, Liu Z. NMDA receptor regulation of levodopa-induced behavior and changes in striatal G protein-coupled receptor kinase 6 and beta-arrestin-1 expression in parkinsonian rats. Clin Interv Aging. 2013;8:347–52.

    CAS  PubMed  PubMed Central  Google Scholar 

  82. Bezard E, Gross CE, Qin L, Gurevich VV, Benovic JL, Gurevich EV. L-DOPA reverses the MPTP-induced elevation of the arrestin2 and GRK6 expression and enhanced ERK activation in monkey brain. Neurobiol Dis. 2005;18(2):323–35.

    Article  CAS  PubMed  Google Scholar 

  83. Bychkov ER, Gurevich VV, Joyce JN, Benovic JL, Gurevich EV. Arrestins and two receptor kinases are upregulated in Parkinson’s disease with dementia. Neurobiol Aging. 2008;29(3):379–96.

    Article  CAS  PubMed  Google Scholar 

  84. Blandini F, Greenamyre JT. Protective and symptomatic strategies for therapy of Parkinson’s disease. Drugs Today (Barc). 1999;35(6):473–83.

    Article  CAS  PubMed  Google Scholar 

  85. LeWitt PA, Fahn S. Levodopa therapy for Parkinson disease: a look backward and forward. Neurology. 2016;86(14 Suppl 1):S3-12.

    Article  CAS  PubMed  Google Scholar 

  86. Cotzias GC, Papavasiliou PS, Gellene R. Modification of Parkinsonism–chronic treatment with L-dopa. N Engl J Med. 1969;280(7):337–45.

    Article  CAS  PubMed  Google Scholar 

  87. Stocchi F, Nordera G, Marsden CD. Strategies for treating patients with advanced Parkinson’s disease with disastrous fluctuations and dyskinesias. Clin Neuropharmacol. 1997;20(2):95–115.

    Article  CAS  PubMed  Google Scholar 

  88. Pavon N, Martin AB, Mendialdua A, Moratalla R. ERK phosphorylation and FosB expression are associated with L-DOPA-induced dyskinesia in hemiparkinsonian mice. Biol Psychiatry. 2006;59(1):64–74.

    Article  CAS  PubMed  Google Scholar 

  89. Santini E, Heiman M, Greengard P, Valjent E, Fisone G. Inhibition of mTOR signaling in Parkinson’s disease prevents L-DOPA-induced dyskinesia. Sci Signal. 2009;2(80):36.

    Article  Google Scholar 

  90. Santini E, Valjent E, Usiello A, Carta M, Borgkvist A, Girault JA, et al. Critical involvement of cAMP/DARPP-32 and extracellular signal-regulated protein kinase signaling in L-DOPA-induced dyskinesia. J Neurosci. 2007;27(26):6995–7005.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  91. Bateup HS, Santini E, Shen W, Birnbaum S, Valjent E, Surmeier DJ, et al. Distinct subclasses of medium spiny neurons differentially regulate striatal motor behaviors. Proc Natl Acad Sci USA. 2010;107(33):14845–50.

    Article  CAS  PubMed  Google Scholar 

  92. Kovoor A, Seyffarth P, Ebert J, Barghshoon S, Chen CK, Schwarz S, et al. D2 dopamine receptors colocalize regulator of G-protein signaling 9–2 (RGS9-2) via the RGS9 DEP domain, and RGS9 knock-out mice develop dyskinesias associated with dopamine pathways. J Neurosci. 2005;25(8):2157–65.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  93. Gold SJ, Hoang CV, Potts BW, Porras G, Pioli E, Kim KW, et al. RGS9-2 negatively modulates L-3,4-dihydroxyphenylalanine-induced dyskinesia in experimental Parkinson’s disease. J Neurosci. 2007;27(52):14338–48.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  94. Urs NM, Bido S, Peterson SM, Daigle TL, Bass CE, Gainetdinov RR, et al. Targeting beta-arrestin2 in the treatment of L-DOPA-induced dyskinesia in Parkinson’s disease. Proc Natl Acad Sci USA. 2015;112(19):E2517–26.

    Article  CAS  PubMed  Google Scholar 

  95. Sotnikova TD, Beaulieu JM, Barak LS, Wetsel WC, Caron MG, Gainetdinov RR. Dopamine-independent locomotor actions of amphetamines in a novel acute mouse model of Parkinson disease. PLoS Biol. 2005;3(8):e271.

    Article  PubMed  PubMed Central  Google Scholar 

  96. Zhang XR, Zhang ZR, Chen SY, Wang WW, Wang XS, He JC, et al. beta-arrestin2 alleviates L-dopa-induced dyskinesia via lower D1R activity in Parkinson’s rats. Aging (Albany NY). 2019;11(24):12315–27.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  97. Martini ML, Liu J, Ray C, Yu X, Huang XP, Urs A, et al. Defining structure-functional selectivity relationships (SFSR) for a class of non-catechol dopamine D1 receptor agonists. J Med Chem. 2019;62(7):3753–72.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  98. Martini ML, Ray C, Yu X, Liu J, Pogorelov VM, Wetsel WC, et al. Designing functionally selective noncatechol dopamine D1 receptor agonists with potent in vivo antiparkinsonian activity. ACS Chem Neurosci. 2019;10(9):4160–82.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  99. Park H, Urs AN, Zimmerman J, Liu C, Wang Q, Urs NM. Structure-functional-selectivity relationship studies of novel apomorphine analogs to develop D1R/D2R biased ligands. ACS Med Chem Lett. 2020;11(3):385–92.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  100. Gray DL, Allen JA, Mente S, O’Connor RE, DeMarco GJ, Efremov I, et al. Impaired beta-arrestin recruitment and reduced desensitization by non-catechol agonists of the D1 dopamine receptor. Nat Commun. 2018;9(1):674.

    Article  PubMed  PubMed Central  Google Scholar 

  101. McCorvy JD, Butler KV, Kelly B, Rechsteiner K, Karpiak J, Betz RM, et al. Structure-inspired design of beta-arrestin-biased ligands for aminergic GPCRs. Nat Chem Biol. 2018;14(2):126–34.

    Article  CAS  PubMed  Google Scholar 

  102. Listos J, Lupina M, Talarek S, Mazur A, Orzelska-Gorka J, Kotlinska J. The mechanisms involved in morphine addiction: an overview. Int J Mol Sci. 2019;20:17.

    Article  Google Scholar 

  103. Drugs UNOo, Crime, Drugs UNOO, Crime. World Drug Report 2017. United Nation Office on Drugs and Crime Vienna; 2017.

  104. Rose SJ, Pack TF, Peterson SM, Payne K, Borrelli E, Caron MG. Engineered D2R variants reveal the balanced and biased contributions of G-protein and beta-arrestin to dopamine-dependent functions. Neuropsychopharmacology. 2018;43(5):1164–73.

    Article  CAS  PubMed  Google Scholar 

  105. Donthamsetti P, Gallo EF, Buck DC, Stahl EL, Zhu Y, Lane JR, et al. Arrestin recruitment to dopamine D2 receptor mediates locomotion but not incentive motivation. Mol Psychiatry. 2020;25(9):2086–100.

    Article  CAS  PubMed  Google Scholar 

  106. Urs NM, Caron MG. The physiological relevance of functional selectivity in dopamine signalling. Int J Obes Suppl. 2014;4(Suppl 1):S5-8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  107. Smith JW, Fetsko LA, Xu R, Wang Y. Dopamine D2L receptor knockout mice display deficits in positive and negative reinforcing properties of morphine and in avoidance learning. Neuroscience. 2002;113(4):755–65.

    Article  CAS  PubMed  Google Scholar 

  108. St-Gelais F, Jomphe C, Trudeau LE. The role of neurotensin in central nervous system pathophysiology: what is the evidence? J Psychiatry Neurosci. 2006;31(4):229–45.

    PubMed  PubMed Central  Google Scholar 

  109. Ferraro L, Tiozzo Fasiolo L, Beggiato S, Borelli AC, Pomierny-Chamiolo L, Frankowska M, et al. Neurotensin: a role in substance use disorder? J Psychopharmacol. 2016;30(2):112–27.

    Article  CAS  PubMed  Google Scholar 

  110. Binder EB, Kinkead B, Owens MJ, Nemeroff CB. Neurotensin and dopamine interactions. Pharmacol Rev. 2001;53(4):453–86.

    CAS  PubMed  Google Scholar 

  111. Borroto-Escuela DO, Ravani A, Tarakanov AO, Brito I, Narvaez M, Romero-Fernandez W, et al. Dopamine D2 receptor signaling dynamics of dopamine D2-neurotensin 1 receptor heteromers. Biochem Biophys Res Commun. 2013;435(1):140–6.

    Article  CAS  PubMed  Google Scholar 

  112. Fantegrossi WE, Ko MC, Woods JH, Richelson E. Antinociceptive, hypothermic, hypotensive, and reinforcing effects of a novel neurotensin receptor agonist, NT69L, in rhesus monkeys. Pharmacol Biochem Behav. 2005;80(2):341–9.

    Article  CAS  PubMed  Google Scholar 

  113. Pettibone DJ, Hess JF, Hey PJ, Jacobson MA, Leviten M, Lis EV, et al. The effects of deleting the mouse neurotensin receptor NTR1 on central and peripheral responses to neurotensin. J Pharmacol Exp Ther. 2002;300(1):305–13.

    Article  CAS  PubMed  Google Scholar 

  114. Tabarean IV. Neurotensin induces hypothermia by activating both neuronal neurotensin receptor 1 and astrocytic neurotensin receptor 2 in the median preoptic nucleus. Neuropharmacology. 2020;171:108069.

    Article  CAS  PubMed  Google Scholar 

  115. Slosky LM, Bai Y, Toth K, Ray C, Rochelle LK, Badea A, et al. beta-arrestin-biased allosteric modulator of NTSR1 selectively attenuates addictive behaviors. Cell. 2020;181(6):1364–79.

    Article  CAS  PubMed  Google Scholar 

  116. Delporte C. Structure and physiological actions of ghrelin. Scientifica (Cairo). 2013;2013:518909.

    PubMed  PubMed Central  Google Scholar 

  117. Abizaid A, Liu ZW, Andrews ZB, Shanabrough M, Borok E, Elsworth JD, et al. Ghrelin modulates the activity and synaptic input organization of midbrain dopamine neurons while promoting appetite. J Clin Investig. 2006;116(12):3229–39.

    Article  CAS  PubMed  Google Scholar 

  118. Zigman JM, Jones JE, Lee CE, Saper CB, Elmquist JK. Expression of ghrelin receptor mRNA in the rat and the mouse brain. J Comp Neurol. 2006;494(3):528–48.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  119. Quarta D, Di Francesco C, Melotto S, Mangiarini L, Heidbreder C, Hedou G. Systemic administration of ghrelin increases extracellular dopamine in the shell but not the core subdivision of the nucleus accumbens. Neurochem Int. 2009;54(2):89–94.

    Article  CAS  PubMed  Google Scholar 

  120. Abizaid A, Mineur YS, Roth RH, Elsworth JD, Sleeman MW, Picciotto MR, et al. Reduced locomotor responses to cocaine in ghrelin-deficient mice. Neuroscience. 2011;29(192):500–6.

    Article  Google Scholar 

  121. Toth K, Slosky LM, Pack TF, Urs NM, Boone P, Mao L, et al. Ghrelin receptor antagonism of hyperlocomotion in cocaine-sensitized mice requires betaarrestin-2. Synapse. 2018;72:1.

    Article  Google Scholar 

  122. Evron T, Peterson SM, Urs NM, Bai Y, Rochelle LK, Caron MG, et al. G Protein and beta-arrestin signaling bias at the ghrelin receptor. J Biol Chem. 2014;289(48):33442–55.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  123. Seth P, Scholl L, Rudd RA, Bacon S. Overdose deaths involving opioids, cocaine, and psychostimulants—United States, 2015–2016. MMWR Morb Mortal Wkly Rep. 2018;67(12):349–58.

    Article  PubMed  PubMed Central  Google Scholar 

  124. Azadfard M, Huecker MR, Leaming JM. Opioid addiction. Treasure Island (FL): StatPearls; 2020.

    Google Scholar 

  125. Bodnar RJ. Endogenous opiates and behavior: 2013. Peptides. 2014;62:67–136.

    Article  CAS  PubMed  Google Scholar 

  126. Wise RA. Opiate reward: sites and substrates. Neurosci Biobehav Rev. 1989;13(2–3):129–33.

    Article  CAS  PubMed  Google Scholar 

  127. Bohn LM, Lefkowitz RJ, Caron MG. Differential mechanisms of morphine antinociceptive tolerance revealed in (beta)arrestin-2 knock-out mice. J Neurosci. 2002;22(23):10494–500.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  128. Raehal KM, Bohn LM. The role of beta-arrestin2 in the severity of antinociceptive tolerance and physical dependence induced by different opioid pain therapeutics. Neuropharmacology. 2011;60(1):58–65.

    Article  CAS  PubMed  Google Scholar 

  129. Azevedo Neto J, Costanzini A, De Giorgio R, Lambert DG, Ruzza C, Calo G. Biased versus Partial Agonism in the search for safer opioid analgesics. Molecules. 2020;25:17.

    Article  Google Scholar 

  130. Beck TC, Hapstack MA, Beck KR, Dix TA. Therapeutic potential of kappa opioid agonists. Pharmaceuticals (Basel). 2019;12:2.

    Article  Google Scholar 

  131. Di Chiara G, Imperato A. Opposite effects of mu and kappa opiate agonists on dopamine release in the nucleus accumbens and in the dorsal caudate of freely moving rats. J Pharmacol Exp Ther. 1988;244(3):1067–80.

    PubMed  Google Scholar 

  132. Bals-Kubik R, Ableitner A, Herz A, Shippenberg TS. Neuroanatomical sites mediating the motivational effects of opioids as mapped by the conditioned place preference paradigm in rats. J Pharmacol Exp Ther. 1993;264(1):489–95.

    CAS  PubMed  Google Scholar 

  133. Mores KL, Cummins BR, Cassell RJ, van Rijn RM. A review of the therapeutic potential of recently developed G protein-biased kappa agonists. Front Pharmacol. 2019;10:407.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  134. Brust TF, Morgenweck J, Kim SA, Rose JH, Locke JL, Schmid CL, et al. Biased agonists of the kappa opioid receptor suppress pain and itch without causing sedation or dysphoria. Sci Signal. 2016;9(456):117.

    Article  Google Scholar 

  135. White KL, Robinson JE, Zhu H, DiBerto JF, Polepally PR, Zjawiony JK, et al. The G protein-biased kappa-opioid receptor agonist RB-64 is analgesic with a unique spectrum of activities in vivo. J Pharmacol Exp Ther. 2015;352(1):98–109.

    Article  PubMed  PubMed Central  Google Scholar 

  136. Hilger D, Masureel M, Kobilka BK. Structure and dynamics of GPCR signaling complexes. Nat Struct Mol Biol. 2018;25(1):4–12.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pharmacology and Therapeutics, University of Florida, 1200 Newell Dr, ARB-R5-140, Gainesville, FL, 32610, USA

    Sharonda S. Harris & Nikhil M. Urs

Authors
  1. Sharonda S. Harris
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nikhil M. Urs
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Nikhil M. Urs.

Ethics declarations

Funding

We would like to thank the Michael J. Fox Foundation (MJFF) and the Brain and Behavior Research Foundation (BBRF) (formally, the National Alliance for Research on Schizophrenia and Depression [NARSAD]) for partially funding our research program at the University of Florida.

Conflict of interest

The authors have no conflicts of interest to declare.

Author contributions

SSH and NMU wrote the manuscript.

Ethics approval

Not applicable.

Consent to participate

Not applicable.

Availability of data

Not applicable.

Rights and permissions

Reprints and Permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Harris, S.S., Urs, N.M. Targeting β-Arrestins in the Treatment of Psychiatric and Neurological Disorders. CNS Drugs 35, 253–264 (2021). https://doi.org/10.1007/s40263-021-00796-y

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40263-021-00796-y

search

Navigation